Evidence map›Paper›PMID 38597967›Full record

ArticleCellular and molecular life sciences : CMLS2024

PALB2-mutated human mammary cells display a broad spectrum of morphological and functional abnormalities induced by increased TGFβ signaling.

Hanna Tuppurainen, Niina Laurila, Marjut Nätynki, Leila Eshraghi, Anna Tervasmäki, Louisa Erichsen, Claus Storgaard Sørensen, Katri Pylkäs, Robert Winqvist, Hellevi Peltoketo

Open access · goldAbstract read
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Integrative Analysis ofInternational journal of molecular sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Hanna Tuppurainen *Laboratory of Cancer Genetics and Tumor Biology, Translational Medicine Research Unit, Biocenter Oulu and Faculty of Medicine, Medical Research Center Oulu, University of Oulu, Oulu, Finland.ORCID http://orcid.org/0000-0001-5997-9266
Niina Laurila *Laboratory of Cancer Genetics and Tumor Biology, Translational Medicine Research Unit, Biocenter Oulu and Faculty of Medicine, Medical Research Center Oulu, University of Oulu, Oulu, Finland.ORCID http://orcid.org/0000-0002-4880-0504
Marjut NätynkiLaboratory of Cancer Genetics and Tumor Biology, Translational Medicine Research Unit, Biocenter Oulu and Faculty of Medicine, Medical Research Center Oulu, University of Oulu, Oulu, Finland.ORCID http://orcid.org/0000-0003-0581-2529
Leila EshraghiLaboratory of Cancer Genetics and Tumor Biology, Translational Medicine Research Unit, Biocenter Oulu and Faculty of Medicine, Medical Research Center Oulu, University of Oulu, Oulu, Finland.ORCID http://orcid.org/0000-0003-1012-689X
Anna TervasmäkiLaboratory of Cancer Genetics and Tumor Biology, Translational Medicine Research Unit, Biocenter Oulu and Faculty of Medicine, Medical Research Center Oulu, University of Oulu, Oulu, Finland.ORCID http://orcid.org/0000-0002-0687-2120
Louisa ErichsenBiotech Research and Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark.
Claus Storgaard SørensenBiotech Research and Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark.ORCID http://orcid.org/0000-0001-6022-9710
Katri PylkäsLaboratory of Cancer Genetics and Tumor Biology, Translational Medicine Research Unit, Biocenter Oulu and Faculty of Medicine, Medical Research Center Oulu, University of Oulu, Oulu, Finland.ORCID http://orcid.org/0000-0002-2449-0521
Robert Winqvist *Laboratory of Cancer Genetics and Tumor Biology, Translational Medicine Research Unit, Biocenter Oulu and Faculty of Medicine, Medical Research Center Oulu, University of Oulu, Oulu, Finland. robert.winqvist@oulu.fi.ORCID http://orcid.org/0000-0003-0932-9104
Hellevi Peltoketo *Laboratory of Cancer Genetics and Tumor Biology, Translational Medicine Research Unit, Biocenter Oulu and Faculty of Medicine, Medical Research Center Oulu, University of Oulu, Oulu, Finland. hellevi.peltoketo@oulu.fi.ORCID http://orcid.org/0000-0003-4019-0091
University of Oulu · FIOulu University Hospital · FIUniversity of Copenhagen · DKGarvan Institute of Medical Research · AU

Funding

Academy of Finland 314183Academy of Finland 318337
6 · The paper itself

Abstract

Heterozygous mutations in any of three major genes, BRCA1, BRCA2 and PALB2, are associated with high-risk hereditary breast cancer susceptibility frequently seen as familial disease clustering. PALB2 is a key interaction partner and regulator of several vital cellular activities of BRCA1 and BRCA2, and is thus required for DNA damage repair and alleviation of replicative and oxidative stress. Little is however known about how PALB2-deficiency affects cell function beyond that, especially in the three-dimensional setting, and also about its role during early steps of malignancy development. To answer these questions, we have generated biologically relevant MCF10A mammary epithelial cell lines with mutations that are comparable to certain clinically important PALB2 defects. We show in a non-cancerous background how both mono- and biallelically PALB2-mutated cells exhibit gross spontaneous DNA damage and mitotic aberrations. Furthermore, PALB2-deficiency disturbs three-dimensional spheroid morphology, increases the migrational capacity and invasiveness of the cells, and broadly alters their transcriptome profiles. TGFβ signaling and KRT14 expression are enhanced in PALB2-mutated cells and their inhibition and knock down, respectively, lead to partial restoration of cell functions. KRT14-positive cells are also more abundant with DNA damage than KRT14-negative cells. The obtained results indicate comprehensive cellular changes upon PALB2 mutations, even in the presence of half dosage of wild type PALB2 and demonstrate how PALB2 mutations may predispose their carriers to malignancy.

Indexed as

NeoplasmsSignal TransductionBreastDNA RepairEpithelial CellsFanconi Anemia Complementation Group N ProteinHumansFanconi Anemia Complementation Group N ProteinPALB2 protein, humanHereditary breast cancer susceptibility modelingKRT14-positive cellsPALB2-edited cell linesTGFβ responseThree-dimensional cell growth and migrationTranscriptome profiling

Identifiers

PMID38597967
PMCPMC11006627
OpenAlexW4394690827

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.